Hope for transplant patients: new drug shows promise in Long-Term rejection fight
NCT ID NCT07444489
First seen Mar 05, 2026 · Last updated May 18, 2026 · Updated 9 times
Summary
This study looks at the long-term safety of felzartamab in people who have had a kidney transplant and developed antibody-mediated rejection (AMR), where the immune system attacks the new kidney. Participants who completed an earlier study can receive felzartamab for up to 4 more years. Researchers will monitor side effects, kidney health through biopsies, and overall well-being.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-MEDIATED REJECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cooperman Barnabas Medical Center
West Orange, New Jersey, 07039, United States
-
UCLA College of Medicine
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.